Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (4702)	3/29/1999 11:27:00 AM
From: Bucky Katt	Respond to of 57584

Yep I agree. Some of us carp fishers were buying PLAT, knew the story, waited. Now, look at the gain.... BTW, another "carp" we all know well, BIPL, is getting some buy action today. Came out with positive earnings, still has delist hanging, but I think they would reverse before a delist. Looks like it is being bought/set/up for a run to the dollar area. Look at VERT!!

To: Rande Is who wrote (4702)	3/29/1999 12:02:00 PM
From: Bucky Katt	Read Replies (1) \| Respond to of 57584

RE: BIPL- this Mayo clinic news is worth a buck to the stock price> Biopool International Announces Results of New Mayo Clinic D-Dimer Study VENTURA, Calif.--(BW HealthWire)--March 29, 1999--Biopool International Inc. (Nasdaq:BIPL - news) Monday announced the results of a new study conducted at the Mayo Clinic by Dr. John A. Heit and his colleagues that indicates Biopool's Minutex® D-dimer test kit can save time, money, avoid invasive testing and improve patient outcomes in the diagnosis of pulmonary embolism (PE), an often lethal disease resulting from the occlusion of blood vessels leading from the lungs to the heart. The Minutex® D-dimer kit, currently Biopool's largest-selling hemostasis product, is a latex agglutination assay for the rapid detection of elevated levels of fibrin D-dimer (the breakdown product of a fibrin clot) in plasma, a key indicator of thrombotic disorders such as PE and deep vein thrombosis (DVT). The study, published in the March 1999 issue of Archives of Pathological Laboratory Medicine, states: ''Standard anticoagulation therapy for pulmonary embolism is effective but may have severe and even life-threatening complications. Therefore, a diagnosis of pulmonary embolism must be sufficiently certain for the affected to receive potentially life-saving therapy and the unaffected to avoid needless risk. However, current diagnostic tests for pulmonary embolism are complex, time-consuming, expensive, potentially hazardous, and often unavailable. Moreover, only about one third of patients with suspected pulmonary embolism are ultimately proved to be affected.''